CARsgen Therapeutics (HKG:2171) presented the updated results of three drugs at the 66th Annual Congress of the American Society of Hematology, a Tuesday bourse filing said.
Two of the drugs, CT0590 and CT071, are currently being tested for the treatment of relapsed/refractory multiple myeloma, while Zevorcabtagene autoleucel has been approved for the same purpose by China's National Medical Products Administration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.